Search

Displaying results 6951 - 6960 of 7041 in total
  1. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor, an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR
  2. Drug

    CTX120

    go.drugbank.com/drugs/DB18625
    Investigational

    CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen
  3. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen
  4. Drug

    Zedenoleucel

    go.drugbank.com/drugs/DB18639
    Investigational

    MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.

  5. Drug

    ALLO-715

    go.drugbank.com/drugs/DB18640
    Investigational

    ALLO-715 is an allogeneic chimeric antigen receptor T Cell therapy targeting B cell maturation antigen (BCMA).

    Synonyms: Allogenic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen (BCMA)
  6. Drug

    Lacutamab

    go.drugbank.com/drugs/DB15322
    Investigational

    Lacutamab is under investigation in clinical trial NCT02593045 (Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL)).

  7. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    Preclinical trials showed the vaccine candidate produced high levels of neutralizing antibodies, and induced a strong T-cell response.

  8. Drug

    SNS01-T

    go.drugbank.com/drugs/DB17302
    Investigational

    SNS01-T is a gene therapy nanoparticle.

  9. Drug

    Maveropepimut-S

    go.drugbank.com/drugs/DB17339
    Investigational

    Maveropepimut-S is a T cell activating immunotherapy.

  10. Drug

    L-3972-T

    go.drugbank.com/drugs/DB17441
    Experimental

    L-3972-T is one of the components of the human papilloma virus (HPV) type 16 E6/E7 synthetic long peptide (SLP) vaccine ISA101b.

    Synonyms: ISA101B component L-3972-T, Human Papilloma Virus (HPV) Type 16 E6/E7 Synthetic Long Peptide (SLP) Vaccine Component L-3972-T